Authors
Latest:
Analyzing Factors That Lead to Worse Outcomes in Mucosal MelanomaRichard D. Carvajal, MD, discusses what he sees as the leading factors in making outcomes worse for patients with mucosal melanoma and how the disease differs from treatment for patients with cutaneous melanoma.
Latest:
Tebentafusp Shows Significant OS Benefit in Advanced Uveal MelanomaRichard D. Carvajal, MD, discusses the mechanism of action and efficacy of tebentafusp-tebn for patients with uveal melanoma.
Latest:
The Expansion of Treatment in the Firstline Setting of HCCRichard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.
Latest:
Exploring the Future Treatment Landscape of Hepatocellular CarcinomaRichard S. Finn, MD, discusses how he sees the field of hepatocellular carcinoma evolving in the future.
Latest:
Richard Gray on the Safety and Efficacy of 10 Years of Adjuvant TamoxifenRichard G. Gray, MA, MSc, discusses results from the randomized, phase III aTTom study that examined 10 years of tamoxifen versus the more standard 5 years.
Latest:
Results from the Phase III CALGB/SWOG 80405 TrialRichard Goldberg, MD, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting.
Latest:
The Impact of SequestrationRichard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses the impact that sequestration had on the FDA.
Latest:
Monitoring MRD in Patients with AMLRichard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).
Latest:
Requirements for a Breakthrough Therapy DesignationRichard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.
Latest:
Identifying Differences Between BTK Inhibitors for B-Cell MalignanciesRichard R. Furman, MD, discusses the distinguishing features between the 3 different Bruton’s tyrosine kinase inhibitors as treatment of patients with B-cell malignancies.
Latest:
What Will Be the Next Frontline Therapy for HCC?UCLA professor, Richard S. Finn, MD, discusses the next possible regimen for hepatocellular carcinoma.
Latest:
An Overview of the CALGB 10603 Trial in AMLRichard M. Stone, MD, Program Director, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the CALGB 10603 trial, which explored the use of midostaurin as a treatment for patients with FLT3-mutated acute myeloid leukemia.
Latest:
SOLO3 Reviews Potential Toxicities With Olaparib in Ovarian CancerRichard T. Penson, MD, discusses the toxicities that were demonstrated in the long-term follow-up of the phase III SOLO3 trial. This multicenter, open-label trial investigated single-agent olaparib in patients with platinum-sensitive, relapsed, BRCA-mutated ovarian cancer who have received at least 2 prior lines of chemotherapy.
Latest:
Key Takeaways on Interferon Use in Myeloproliferative NeoplasmsRichard Silver, MD, discusses the Interferon Initiative organized by the Myeloproliferative Neoplasm Research Foundation.
Latest:
Dr. Rimas Lukas on Searching for Biomarkers in Glioblastoma​Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, discusses the next steps following a phase I study looking at atezolizumab in glioblastoma.
Latest:
Perioperative Nivolumab/Ipilimumab Combo Showing Early Promising Results in HCCPathologic complete responses were seen in 29% of patients with resectable hepatocellular carcinoma treated with a perioperative immunotherapy regimen in the first interim analysis of a phase II trial, reported Yehia I. Abugabal, MD, in his presentation at the 2019 ILCA Annual Conference.
Latest:
The IMpassion130 trial in Metastatic Triple-Negative Breast CancerRita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.
Latest:
Ovarian Cancer Maintenance Therapy With BevacizumabRobert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
Latest:
Lenvatinib/Everolimus Shows Potential as Second-Line Therapy After CheckMate 9ER Regimen in RCCThe CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.
Latest:
Exploring the Role of T-VEC in the Treatment of Metastatic MelanomaRobert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses a study exploring the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with metastatic melanoma.
Latest:
Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLCRobert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with <em>ROS1</em>-positive non–small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are <em>ROS1</em>-positive.
Latest:
Optimizing Prostate Cancer Care Moving Beyond PSARobert Dreicer, MD, MS, MACP, FASCO, discusses the limitations of using prostate-specific antigen levels alone to guide prostate cancer treatment.
Latest:
Dr. Robert Figlin on the Increasingly Complicated Treatment Paradigm for Renal Cell CarcinomaFiglin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.
Latest:
An Overview of the HYBRID Study in Elderly Patients With Bladder CancerRobert Huddart, professor, The Institute of Cancer Research, discusses the HYBRID trial which assessed hypofractionated bladder radiotherapy with or without image guided adaptive planning in elderly patients with bladder cancer.
Latest:
Future Management of nccRCCDr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.
Latest:
Advances in Image-Guided Oncologic TreatmentAdvances in the computerization of the imaging, blood flow, and tumor measures of exact volume and vessel density are now less operator dependent. That provides for an accurate and repeatable diagnosis, and a means to follow the individual patient’s unique pattern of cancer development, progress, and response to treatment.
Latest:
Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium StudyResults from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
